This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
BACKGROUND: The treatment of cystic fibrosis involves the use of drugs delivered by nebulizer systems, and adequate functioning of the compressors and nebulizers is essential. We hypothesized that compressors of nebulizer systems used by individuals with cystic fibrosis would not work properly. Therefore, we aimed to assess the performance of the compressors from nebulizer systems used by individuals with cystic fibrosis.
METHODS: This is a cross-sectional study to assess the performance of compressors from nebulizer systems used by subjects with cystic fibrosis registered at the Cystic Fibrosis Patient Association in Minas Gerais, Brazil. Compressors (Proneb Ultra II) brought by the individuals were tested with new nebulizer parts (Pari LC plus) to assess the variables of nebulization efficiency, including residual volume, solution output, and aerosol output rate. Compression performance was assessed by measuring the operating pressure using a PARI PG101 manometer.
RESULTS: The performance of 146 compressors was analyzed. Fifty-seven (39%) of the compressors were ineffective, with operating pressure values well below the manufacturer's technical reference and the compressor time used for a median time of 36 (15 days to 156 months). The systems with low pressure values demonstrated significantly worse results for nebulization efficiency variables, and a significant correlation was found between residual volume (r = –0.5, P < .001), solution output (r = +0.5, P < .001), and aerosol output rate (r = +0.5, P < .001), and operating pressure values.
CONCLUSIONS: A significant number of compressors generate low operating pressure values. These systems showed a compromised efficiency of nebulization, indicating that the pressure generated by the compressor is a critical aspect of treatment efficiency.
- cystic fibrosis
- jet nebulizer
- compressor
- nebulizer delivered volume
- residual volume
- aerosol therapy
- nebulizer operating pressure
Footnotes
- Correspondence: Evanirso S Aquino PT PhD, João Paulo II Pediatric Hospital, Fundação Hospital of the State of Minas Gerais, Alameda Ezequiel Dias, 345, Centro, Belo Horizonte MG, 30130-110, Brazil. E-mail: evanirso-aquino{at}uol.com.br
Dr Aquino presented a version of this paper at the Institute of Tropical Medicine of the University of São Paulo on October 05, 2018.
This work was supported by a grant from Novartis Ph armaceuticals. Dr Aquino has disclosed relationships with Vertex Pharmaceuticals and Roche do Brasil. Dr Silva Filho has disclosed relationships with Vertex Pharmaceuticals, Timpel, Diagnostics of America, Roche do Brasil, Boehringer Ingelheim, Glenmark do Brasil, AbbVie, and Sanofi. Dr Vergara has disclosed relationships with Vertex Pharmaceuticals and Roche do Brasil.
Supplementary material related to this paper is available at http://www.rcjournal.com.
- Copyright © 2021 by Daedalus Enterprises
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$30.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
